COGT
HealthcareCogent Biosciences, Inc.
$34.26
$-0.48 (-1.38%)
Jan 5, 2026
Price History (1Y)
Analysis
Cogent Biosciences, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $5.26 billion and 205 employees. The company's financial health reveals a significant net loss of $294.37 million in the trailing twelve months, accompanied by an EBITDA loss of $305.04 million and free cash flow of -$140.29 million. The gross margin, operating margin, and profit margin are all at 0.0%, indicating substantial operational losses. Additionally, Cogent Biosciences has a negative return on equity (-95.4%) and return on assets (-47.5%), suggesting inefficient use of resources. The balance sheet shows a debt-to-equity ratio of 20.02 and $390.89 million in cash reserves against $60.56 million in debt. Cogent Biosciences' valuation metrics include a forward P/E ratio of -19.81, which is not indicative of traditional valuation measures due to the significant net losses incurred by the company. The price-to-book ratio is 24.63, and the enterprise value-to-EBITDA (EV/EBITDA) ratio is -15.49. These metrics do not provide a clear indication of the company's intrinsic value or growth prospects.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $5.26B
- P/E Ratio
- N/A
- 52-Week High
- $43.73
- 52-Week Low
- $3.72
- Avg Volume
- 3.25M
- Beta
- 0.51
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 205